GEA Group Aktiengesellschaft (DAX: GEA), one of the world's largest suppliers of systems and components to the food, beverage and pharmaceutical industries, reported strong third-quarter 2026 results on 9 November 2026, with order intake rising 20.3% to EUR 1,650.7 million and EBITDA margin before restructuring expenses reaching a new quarterly record of 17.9%. The Düsseldorf-headquartered group also confirmed its raised full-year 2026 outlook, targeting organic revenue growth of 6.0% to 8.0%. Investors will be watching whether the high order intake, driven partly by EUR 294.8 million in large orders, translates into sustained revenue momentum through the final quarter.

Key Points

  • GEA Group Aktiengesellschaft (ISIN: DE0006602006, DAX-listed, reference: 0MPJ)
  • Q3 2026 order intake grew 20.3% year-on-year to EUR 1,650.7 million, with organic growth of 19.5%
  • EBITDA margin before restructuring expenses hit a record 17.9%; ROCE reached a record 37.8%; free cash flow rose to EUR 134.7 million from EUR 52.2 million
  • Investors should watch whether Continuous Tableting commercialisation and large-order momentum sustain into Q4 2026 and beyond

Large Orders in Pharma and Nutrition Plant Engineering Drive Q3 Order Intake Surge

Order intake of EUR 1,650.7 million represented a 20.3% increase on the EUR 1,372.4 million recorded in Q3 2025, with all divisions contributing positively. Large orders totalling EUR 294.8 million were a significant factor, compared with just EUR 64.4 million in the prior-year quarter. Of that total, EUR 191.7 million was attributable to the Nutrition Plant Engineering division, with the remaining EUR 103.1 million coming from the Pharma & Food Applications division. Demand was particularly strong across Dairy Processing, Beverage and Pharma customer industries, the announcement states.

GEA's Continuous Tableting Technology Gains Commercial Momentum in Pharmaceutical Sector

A highlight of the quarter was the performance of Continuous Tableting, GEA's technology enabling pharmaceutical tablets to be manufactured faster and more efficiently. Following earlier orders and the commissioning of initial commercial production lines, a large order for Continuous Tableting technologies was received in Q3 2026, the company disclosed. GEA has identified this technology under its "Mission 30" strategy as a growth field it expects to deliver average annual revenue growth (CAGR) of between 15% and 20% through 2030, making it a closely watched driver for the group's longer-term pharmaceutical revenues.

Record EBITDA Margin and ROCE Reflect Improving Profitability Across GEA's Service Business

EBITDA before restructuring expenses rose 12.6% to EUR 260.9 million in Q3 2026, with the corresponding margin improving from 17.0% to a record 17.9%. Net profit increased 6.4% to EUR 128.5 million, while earnings per share before restructuring expenses rose from EUR 0.76 to EUR 0.87. ROCE advanced to a record 37.8% from 35.4%. Service revenue grew to EUR 597.5 million, representing 40.9% of group revenue, with the announcement citing service profitability as a key driver of the margin expansion.

GEA Confirms Raised Full-Year 2026 Outlook as Net Liquidity Turns Positive

GEA confirmed the full-year 2026 guidance it raised in July, targeting organic revenue growth of 6.0% to 8.0%, an EBITDA margin before restructuring expenses of 17.0% to 17.4%, and ROCE of between 36.0% and 40.0%. Net liquidity improved to EUR 115.2 million as of 30 September 2026, compared with net debt of EUR 36.3 million at the prior-year reporting date, despite EUR 54.1 million spent on share buybacks during the quarter. For the first nine months of 2026, group revenue reached EUR 4,176.9 million, up 6.1% year-on-year.